Answers are grounded in this paper and cite their sources.
The feasibility of acquiring clinically relevant histopathologic information on critical underlying amyloid and tau pathology in Alzheimer disease and related diseases is the reason why therapeutic trials now incorporate PET imaging biomarkers in most studies. Specifically, PET is used to assess
No takes yet. Share an insight, caveat, or question.
Barthel et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: